Livzon Pharmaceutical Group Inc. (000513.SZ): Injection JP-1366 approved for clinical trials.

Livzon Pharmaceutical Group Inc. (000513.SZ) announced that the company has received the approval from the National Medical Products Administration to conduct clinical trials for injection use of JP-1366. The announcement states that JP-1366 is a new type of potassium ion competitive acid blocker (P-CAB), which works by competitively binding to the potassium ion binding site of H+/K+-ATPase in gastric wall cells, inhibiting the secretion of gastric acid. P-CAB has the characteristics of quick onset, excellent acid inhibition effect, long-lasting action, small individual differences, and fewer drug interactions. The indication for the clinical trials of injection use of JP-1366 this time is gastrointestinal ulcer bleeding.